MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
DistillerSR Launches Smart Chat, an AI Chat Interface Built Into Its Evidence Platform27.10.2026 15:55:00 CET | Press release
OTTAWA, ON / ACCESS Newswire / October 27, 2026 / DistillerSR® Inc., the pioneer and market leader in AI-enabled literature review automation and evidence management, today announced the launch of Smart Chat. Smart Chat brings DistillerSR's Agentic AI capabilities in-platform. Since September 2025, DistillerSR Agentic AI has eliminated evidence silos at customer organizations by connecting Large Language Models to a repository of expertly validated literature evidence. Smart Chat now makes that same capability available natively within DistillerSR's secure platform. "While researchers recognize the power of generative AI, many life sciences organizations cannot risk connecting external LLMs to their sensitive research data," said Peter O'Blenis, CEO of DistillerSR. "Smart Chat removes that barrier. It is built directly into the platform teams already use, works exclusively with their own DistillerSR projects, and is included with every version of DistillerSR." Smart Chat works only wit
PuK Gaming Launches First Officially Licensed Fortnite Mobile Accessories Range27.10.2026 14:15:00 CET | Press release
LONDON, UK / ACCESS Newswire / October 27, 2026 / PuK Gaming LTD, the UK-based designer of premium mobile gaming accessories, today launched Drop 1 of its officially licensed Fortnite range, in a deal facilitated by Epic Games' licensing agency IMG Licensing. The five-product range offers console-grade control to how millions play Fortnite: on a phone. The PuK Thumbstick, PuK Triggers, PuK Link Cable and PuK Thumb Sleeves attach in seconds, no battery charge or pairing required; the whole ecosystem fits in your pocket. The Hot Drop Bundle includes three of the four products, plus a collector tin and zip case. Every Drop 1 product includes a code for a bonus in-game item, with the Thumbstick granting the Stage Dive Glider and the Hot Drop Bundle granting the Battle Call Emote. "Fortnite defines competitive play for mobile gamers," said Scotty Tidwell, CEO of PuK Gaming. "Drop 1 gives Fortnite players more ways to play on mobile with console-grade low-latency control and precision." PuK
QorusDocs Launches QPilot Workspace, Where People and AI Agents Build Winning Proposals Together27.10.2026 14:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / October 27, 2026 / QorusDocs, the pursuit intelligence platform for professional services, legal, technology services and architecture, engineering and construction (AEC) firms, today launched QPilot Workspace, a shared space where business development teams and AI agents complete every pursuit together, from the moment an opportunity opens to the signed contract. QPilot Workspace is guided by pursuit intelligence that grounds every proposal, pitch and RFP response in a firm's real people, projects and pursuit history. Service firms are fielding more RFPs than ever, according to QorusDocs' research. More than two-thirds (68%) saw proposal volume climb last year, with most having to decline participation in 10 to 19% of the RFPs they receive. "We're responding to more RFPs than ever with shorter turnaround times," said Heather Almquist, senior vice president at Marsh, a leading professional services firm. "One of the hardest parts is pulling together the
Formerra Adjusts Transportation Surcharge Amid Continued Freight and Logistics Pressures27.10.2026 14:00:00 CET | Press release
ROMEOVILLE, IL / ACCESS Newswire / October 27, 2026 / Formerra, a leader in performance materials distribution, announced an increase to its transportation surcharge to address continued cost escalation in the freight and logistics market. Beginning November 2, 2026, a surcharge of $450 per delivery will apply to all shipments across North, Central, and South America. Costs in the freight and logistics market have increased steadily as the industry navigates higher operating costs, tighter capacity, and a shortage of qualified drivers. At the same time, diesel prices reached an all-time high in September. "Freight costs across the Americas remain elevated, and we do not expect these pressures to ease in the near term," said Tom Kelly, Formerra CEO. "The adjustment helps offset market pressures beyond our control while enabling us to maintain the dependable service our customers count on from Formerra." Customers should contact their Formerra representative for more information. About F
Camino and Nittetsu Launch Next Phase of Detailed Engineering for the Puquios Copper Project in Chile with Ausenco27.10.2026 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 27, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that following the successful completion of the Critical Engineering Phase study with Ausenco, the company officially held the kickoff meeting to launch the next phase of detailed engineering services with Ausenco Chile Ltda. ("Ausenco") for the Puquios copper project (the "Puquios Project"). This transition into detailed engineering represents a major step forward in advancing the project, locking in technical specifications, and preparing the Puquios Project for the construction phase. Marcelo Bruna, CEO of the Puquios Joint Venture said, "With the commencement of detailed engineering, the executive team remains focused on strict milestone tracking and cost control as we progress towards breaking ground." Jay Chmelauskas, CEO of Camino further commented, "We are working closely with Nittetsu to finalize agreements to source a pote
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom